Recently, a large body of basic and clinical research has elucidated that the cardioprotective effects of SGLT2 inhibitors in patients with T2DM and non-diabetic patients are independent of their antihyperglycemic effects (118). Here, SLC5A2 is linked to type 2 diabetes mellitus.